BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22032622)

  • 1. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.
    Peng XH; Wang Y; Huang D; Wang Y; Shin HJ; Chen Z; Spewak MB; Mao H; Wang X; Wang Y; Chen ZG; Nie S; Shin DM
    ACS Nano; 2011 Dec; 5(12):9480-93. PubMed ID: 22032622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
    Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
    Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy.
    Ai S; Zhen S; Liu Z; Sun F; He X; Chu F; Guan W; Wang J
    RSC Adv; 2018 Aug; 8(52):30012-30020. PubMed ID: 35547284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetically Targeted Nanocapsules for PAA-Cisplatin-Conjugated Cores in PVA/SPIO Shells via Surfactant-Free Emulsion for Reduced Nephrotoxicity and Enhanced Lung Cancer Therapy.
    Chiang CS; Tseng YH; Liao BJ; Chen SY
    Adv Healthc Mater; 2015 May; 4(7):1066-75. PubMed ID: 25656800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian carcinoma biological nanotherapy: Comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery.
    Zhang Y; Zhang P; Zhu T
    Biomed Pharmacother; 2019 Jan; 109():475-483. PubMed ID: 30399584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.
    Nascimento AV; Gattacceca F; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Nanomedicine (Lond); 2016 Apr; 11(7):767-81. PubMed ID: 26980454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer Functionalized Cisplatin-Albumin Nanoparticles for Targeted Delivery to Epidermal Growth Factor Receptor Positive Cervical Cancer.
    Chen Y; Wang J; Wang J; Wang L; Tan X; Tu K; Tong X; Qi L
    J Biomed Nanotechnol; 2016 Apr; 12(4):656-66. PubMed ID: 27301192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
    Zhang X; Li J; Yan M
    Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.
    Yang L; Mao H; Wang YA; Cao Z; Peng X; Wang X; Duan H; Ni C; Yuan Q; Adams G; Smith MQ; Wood WC; Gao X; Nie S
    Small; 2009 Feb; 5(2):235-43. PubMed ID: 19089838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Poly(ethylene glycol) Complex Nanoparticles for Potential Cancer Therapy: Preparation, In Vitro and In Vivo Evaluation.
    Yu H; Tang Z; Li M; Song W; Zhang D; Zhang Y; Yang Y; Sun H; Deng M; Chen X
    J Biomed Nanotechnol; 2016 Jan; 12(1):69-78. PubMed ID: 27301173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
    Li C; Ge X; Wang L
    Biomed Pharmacother; 2017 Feb; 86():628-636. PubMed ID: 28027539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer.
    Liu P; Gou M; Yi T; Qi X; Xie C; Zhou S; Deng H; Wei Y; Zhao X
    Int J Oncol; 2012 Oct; 41(4):1504-12. PubMed ID: 22825572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of redox-responsive tumor targeted cisplatin nano-delivery system for effective cancer chemotherapy.
    Jia YY; Zhang JJ; Zhang YX; Wang W; Li C; Zhou SY; Zhang BL
    Int J Pharm; 2020 Apr; 580():119190. PubMed ID: 32151664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
    Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
    Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
    Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
    Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrone-targeted PEGylated Liposomal Nanoparticles for Cisplatin (DDP) Delivery in Cervical Cancer.
    Li Q; Zhu M; Li Y; Tang H; Wang Z; Zhang Y; Xie Y; Lv Z; Bao H; Li Y; Liu R; Shen Y; Zheng Y; Miao D; Guo X; Pei J
    Eur J Pharm Sci; 2022 Jul; 174():106187. PubMed ID: 35430381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models.
    Jia D; Wang F; Yang Y; Hu P; Song H; Lu Y; Wang R; Li G; Liu R; Li J; Yuan F
    J Pharm Sci; 2022 Feb; 111(2):450-457. PubMed ID: 34547305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.